Organon & Co., a global healthcare company specializing in women's health, has announced results from their Phase 2 ELENA proof-of-concept study. The study evaluated the investigational candidate OG-6219, an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor, in patients with endometriosis-related pain. The trial did not meet its primary efficacy endpoint, as OG-6219 failed to demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Consequently, Organon plans to discontinue the clinical development program for OG-6219. The study was a randomized, double-blind, placebo-controlled, global multi-center trial involving pre-menopausal women aged 18 to 49 with surgically diagnosed endometriosis.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。